Gregory Bailey Buys 48,780 Shares of Biohaven Ltd. (NYSE:BHVN) Stock

Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey bought 48,780 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was bought at an average price of $41.00 per share, with a total value of $1,999,980.00. Following the purchase, the director now owns 1,574,568 shares in the company, valued at $64,557,288. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Gregory Bailey also recently made the following trade(s):

• On Wednesday, April 24th, Gregory Bailey purchased 25,503 shares of Biohaven stock. The shares were acquired at an average price of $39.18 per share, with a total value of $999,207.54.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $38.54 on Friday. The company has a market cap of $3.40 billion, a P/E ratio of -6.81 and a beta of 1.18. Biohaven Ltd. has a 1 year low of $12.35 and a 1 year high of $62.21. The stock’s fifty day moving average price is $51.32 and its 200-day moving average price is $41.79.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). On average, sell-side analysts anticipate that Biohaven Ltd. will post -5.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a report on Tuesday, April 9th. UBS Group raised their price objective on Biohaven from $59.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. TD Cowen raised their price objective on Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Finally, HC Wainwright raised their price objective on Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a report on Monday, March 4th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $52.13.

Institutional Trading of Biohaven

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Stifel Financial Corp increased its position in Biohaven by 7.9% in the fourth quarter. Stifel Financial Corp now owns 6,225,811 shares of the company’s stock worth $266,465,000 after buying an additional 456,062 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Biohaven by 33.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,134,323 shares of the company’s stock worth $134,150,000 after buying an additional 791,181 shares in the last quarter. Point72 Asset Management L.P. increased its position in Biohaven by 142.2% in the fourth quarter. Point72 Asset Management L.P. now owns 2,483,567 shares of the company’s stock worth $106,297,000 after buying an additional 1,458,072 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Biohaven by 13.1% in the third quarter. Armistice Capital LLC now owns 2,036,000 shares of the company’s stock worth $52,956,000 after acquiring an additional 236,000 shares during the period. Finally, Perceptive Advisors LLC boosted its stake in shares of Biohaven by 129.4% in the fourth quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock worth $73,832,000 after acquiring an additional 973,227 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.